Related references
Note: Only part of the references are listed.Belatacept and Long-Term Outcomes in Kidney Transplantation
Flavio Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras
Brian J. Nankivell et al.
TRANSPLANTATION (2016)
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus
D. A. Mandelbrot et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
OPTN/SRTR 2013 Annual Data Report: Pancreas
R. Kandaswamy et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Tubular dysfunction in renal transplant patients using sirolimus or tacrolimus
Pedro B. Banhara et al.
CLINICAL NEPHROLOGY (2015)
Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study
Klemens Budde et al.
CLINICAL NEPHROLOGY (2015)
The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation
Liu Sheng et al.
CLINICAL TRANSPLANTATION (2015)
Sirolimus and everolimus in kidney transplantation
Dirk Jan A. R. Moes et al.
DRUG DISCOVERY TODAY (2015)
Everolimus and sirolimus in transplantation-related but different
Jost Klawitter et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Rapamycin Inhibition of mTOR Reduces Levels of the Na plus /H plus Exchanger 3 in Intestines of Mice and Humans, Leading to Diarrhea
Jun Yang et al.
GASTROENTEROLOGY (2015)
Sirolimus Therapy in Congenital Hyperinsulinism: A Successful Experience Beyond Infancy
Marta Minute et al.
PEDIATRICS (2015)
Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study
K. Budde et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats
William T. Festuccia et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Chronic rapamycin treatment causes diabetes in male mice
Christine E. Schindler et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2014)
Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis
N. Murakami et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Autophagy activation reduces renal tubular injury induced by urinary proteins
Wei Jing Liu et al.
AUTOPHAGY (2014)
Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation
Junichiro Sageshima et al.
CLINICAL TRANSPLANTATION (2014)
The incidence, management, and evolution of rapamycin-related side effects in kidney transplant recipients
Jacobien Verhave et al.
CLINICAL TRANSPLANTATION (2014)
Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions
Erika B. Rangel
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Mis-regulation of Mammalian Target of Rapamycin (mTOR) Complexes Induced by Albuminuria in Proximal Tubules
Diogo B. Peruchetti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Activation of Glycogen Synthase Kinase 3β Ameliorates Diabetes-induced Kidney Injury
Meenalakshmi M. Mariappan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
New Autophagy Reporter Mice Reveal Dynamics of Proximal Tubular Autophagy
Ling Li et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure-response relationships, and clinical outcomes
Fuad Shihab et al.
TRANSPLANT IMMUNOLOGY (2014)
Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies
Laure-Emmanuelle Croze et al.
TRANSPLANT INTERNATIONAL (2014)
Excellent Outcomes Can Be Achieved in Young Pancreas Transplant Alone Recipients by Addition of Sirolimus to Maintenance Immunosuppression Regimen
M. Porubsky et al.
TRANSPLANTATION PROCEEDINGS (2014)
Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers
Jose Sereno et al.
BIOMED RESEARCH INTERNATIONAL (2014)
The Effect of Everolimus Versus Mycophenolate Upon Proteinuria Following Kidney Transplant and Relationship to Graft Outcomes
A. C. Wiseman et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
OPTN/SRTR 2011 Annual Data Report: Pancreas
R. Kandaswamy et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Impact of Calcineurin-Inhibitor Conversion to mTOR Inhibitor on Renal Allograft Function in a Prednisone-Free Regimen
D. Chhabra et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Planned Randomized Conversion From Tacrolimus to Sirolimus-Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients
H. T. Silva et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Low-Dose Rapamycin Unmasks the Protective Potential of Targeting Intragraft NF-κB for Islet Transplants
Nathan W. Zammit et al.
CELL TRANSPLANTATION (2013)
Rapamycin Ameliorates Proteinuria and Restores Nephrin and Podocin Expression in Experimental Membranous Nephropathy
Stavros Stratakis et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Non-invasive biomarkers to guide management following renal transplantation: the need for a multiplatform approach
Paramit Chowdhury et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2013)
Trends in immunosuppression after pancreas transplantation: what is in the pipeline?
Michael Kimelman et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2013)
Stimulation of Autophagy Improves Endoplasmic Reticulum Stress-Induced Diabetes
Etty Bachar-Wikstrom et al.
DIABETES (2013)
Pancreas Transplant Alone A procedure coming of age
Rainer W. G. Gruessner et al.
DIABETES CARE (2013)
Adverse events associated with mTOR inhibitors
Nicolas Pallet et al.
EXPERT OPINION ON DRUG SAFETY (2013)
mTOR signaling for biological control and cancer
Anya Alayev et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in Lung transplantation
Bijan Ghassemieh et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2013)
Obesity-Mediated Autophagy Insufficiency Exacerbates Proteinuria-induced Tubulointerstitial Lesions
Kosuke Yamahara et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
Guillaume Canaud et al.
NATURE MEDICINE (2013)
Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction
Hung T. Ko et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Cellular Effects of Everolimus and Sirolimus on Podocytes
Sandra Mueller-Krebs et al.
PLOS ONE (2013)
The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway
Xin-Yu Miao et al.
PEPTIDES (2013)
Racial Comparisons of Everolimus Pharmacokinetics and Pharmacodynamics in Adult Kidney Transplant Recipients
David J. Taber et al.
THERAPEUTIC DRUG MONITORING (2013)
Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation
J. Kobashigawa et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Metformin Improves Immunosuppressant Induced Hyperglycemia and Exocrine Apoptosis in Rats
Vijay Shivaswamy et al.
TRANSPLANTATION (2013)
Everolimus-Treated Renal Transplant Recipients Have a More Robust CMV-Specific CD8+ T-Cell Response Compared With Cyclosporine- or Mycophenolate-Treated Patients
Simone H. C. Havenith et al.
TRANSPLANTATION (2013)
GABA Protects Human Islet Cells Against the Deleterious Effects of Immunosuppressive Drugs and Exerts Immunoinhibitory Effects Alone
Gerald J. Prud'homme et al.
TRANSPLANTATION (2013)
Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine Profiling
Adrian Egli et al.
TRANSPLANTATION (2013)
Rapamycin Causes Upregulation of Autophagy and Impairs Islets Function Both In Vitro and In Vivo
M. Tanemura et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study
K. Budde et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus with Cyclosporine After Kidney Transplantation
L. Liefeldt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
CMV Late Phase-Induced mTOR Activation Is Essential for Efficient Virus Replication in Polarized Human Macrophages
M. Poglitsch et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Advantage of Rapamycin Over Mycophenolate Mofetil When Used With Tacrolimus for Simultaneous Pancreas Kidney Transplants: Randomized, Single-Center Trial at 10 Years
G. Ciancio et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Autophagy plays a protective role in endoplasmic reticulum stress-mediated pancreatic β cell death
Alberto Bartolome et al.
AUTOPHAGY (2012)
Constitutive activation of the mTOR signaling pathway within the normal glomerulus
Gearoid M. McMahon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
A. D. Barlow et al.
DIABETOLOGIA (2012)
Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury
Shunsaku Nakagawa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
An evaluation of sirolimus in renal transplantation
Fabian Halleck et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation
Erika B. Rangel
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
A drug safety evaluation of everolimus in kidney transplantation
Hallvard Holdaas et al.
EXPERT OPINION ON DRUG SAFETY (2012)
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice
Shinobu Shimizu et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
Davide P. Cina et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation
Manfred Necking et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome
Rawi Ramadan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor
Vincent Vuiblet et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Delayed mTOR Inhibition with Low Dose of Everolimus Reduces TGFβ Expression, Attenuates Proteinuria and Renal Damage in the Renal Mass Reduction Model
Melania Kurdian et al.
PLOS ONE (2012)
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation
Robert M. Langer et al.
TRANSPLANT INTERNATIONAL (2012)
Impact of Tacrolimus-Sirolimus Maintenance Immunosuppression on Proteinuria and Kidney Function in Pancreas Transplant Alone Recipients
Praveen Kandula et al.
TRANSPLANTATION (2012)
Drug Interaction Between Cyclosporine and mTOR Inhibitors in Experimental Model of Chronic Cyclosporine Nephrotoxicity and Pancreatic Islet Dysfunction
Shang Guo Piao et al.
TRANSPLANTATION (2012)
Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature
Bjoern Nashan et al.
TRANSPLANTATION (2012)
Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients
Bjoern Nashan et al.
TRANSPLANTATION (2012)
Characterization of the transcriptome in isolated and transplanted mouse pancreatic islets Associations with engraftment and dysfunction
Shaheed Merani et al.
ISLETS (2012)
mTOR inhibitor-associated proteinuria in kidney transplant recipients
Fritz Diekmann et al.
TRANSPLANTATION REVIEWS (2012)
A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation
Bertram L. Kasiske et al.
JOURNAL OF TRANSPLANTATION (2012)
Mammalian target of rapamycin and the kidney. I. The signaling pathway
Wilfred Lieberthal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Guidelines for the Diagnosis of Antibody-Mediated Rejection in Pancreas Allografts-Updated Banff Grading Schema
C. B. Drachenberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Maria Pieri et al.
CURRENT DRUG METABOLISM (2011)
Rictor/mTORC2 Is Essential for Maintaining a Balance Between β-Cell Proliferation and Cell Size
Yanyun Gu et al.
DIABETES (2011)
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Markus Goedel et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Ken Inoki et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
Jose Pablo Maroto et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Tuberin/mTOR Pathway Promotes Apoptosis of Tubular Epithelial Cells in Diabetes
Chakradhar Velagapudi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The Changing Role of mTOR Kinase in the Maintenance of Protein Synthesis during Human Cytomegalovirus Infection
Amy J. Clippinger et al.
JOURNAL OF VIROLOGY (2011)
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
Matthew R. Weir et al.
KIDNEY INTERNATIONAL (2011)
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
Klemens Budde et al.
LANCET (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Ablation of TSC2 Enhances Insulin Secretion by Increasing the Number of Mitochondria through Activation of mTORC1
Maki Koyanagi et al.
PLOS ONE (2011)
Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins
Giovanni Stallone et al.
TRANSPLANTATION (2011)
Influence of Donor Age on Islet Isolation and Transplantation Outcome
Nadja Niclauss et al.
TRANSPLANTATION (2011)
Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate
Ji Young Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
GSK3β inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility
Britta George et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients
H. Tedesco Silva et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats
Shunsaku Nakagawa et al.
BIOCHEMICAL PHARMACOLOGY (2010)
mTOR inhibitor-associated dermatologic and mucosal problems
Josep M. Campistol et al.
CLINICAL TRANSPLANTATION (2010)
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde et al.
DIABETES (2010)
Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice
Bjoern Hartleben et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
Ryan J. O. Dowling et al.
SCIENCE (2010)
Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients
Eberhard Wieland et al.
THERAPEUTIC DRUG MONITORING (2010)
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study
M. Vigano et al.
TRANSPLANT INFECTIOUS DISEASE (2010)
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial
Jacques Dantal et al.
TRANSPLANT INTERNATIONAL (2010)
Comparing an Early Corticosteroid/Late Calcineurin-Free Immunosuppression Protocol to a Sirolimus-, Cyclosporine A-, and Prednisone-Based Regimen for Pancreas-Kidney Transplantation
Richard J. Knight et al.
TRANSPLANTATION (2010)
Interaction Between Everolimus and Tacrolimus in Renal Transplant Recipients: A Pharmacokinetic Controlled Trial
Julio Pascual et al.
TRANSPLANTATION (2010)
Similar Early Complication Rate in Simultaneous Pancreas and Kidney Recipients on Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus Immunosuppressive Regimens
P. Girman et al.
TRANSPLANTATION PROCEEDINGS (2010)
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
Y. Lebranchu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Posttransplant anemia: the role of sirolimus
Steven Fishbane et al.
KIDNEY INTERNATIONAL (2009)
The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy
Josep M. Grinyo et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation
Josep M. Campistol et al.
TRANSPLANT INTERNATIONAL (2009)
Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial
Maurizio Salvadori et al.
TRANSPLANTATION (2009)
Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus
Laetitia Albano et al.
TRANSPLANTATION (2009)
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Francesco P. Schena et al.
TRANSPLANTATION (2009)
Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients
B. L. Kasiske et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Sirolimus may reduce fertility in male renal transplant recipients
J. Zuber et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Sirolimus is associated with new-onset diabetes in kidney transplant recipients
Olwyn Johnston et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner
Latif Rachdi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome- a single-centre experience and review of the literature
Stefan M. Weiner et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Sirolimus modifies cholesterol Homeostasis in hepatic cells: A potential molecular mechanism for Sirolimus-Associated Dyslipidemia
Kun L. Ma et al.
TRANSPLANTATION (2007)
Late introduction of sirolimus induces anemia in renal transplant recipients
Olivier Thaunat et al.
TRANSPLANTATION (2007)
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects
Christian Toso et al.
TRANSPLANTATION (2007)
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
Daniel Cho et al.
CLINICAL CANCER RESEARCH (2007)
Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview
Eric Huyghe et al.
TRANSPLANT INTERNATIONAL (2007)
Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction
R. K. Wali et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Rapamycin prevents early steps of the development of diabetic nephropathy in rats
Yi Yang et al.
AMERICAN JOURNAL OF NEPHROLOGY (2007)
Switching immunosuppression medications after renal transplantation - a common practice
Herwig-Ulf Meier-Kriesche et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
Acne in recipients of renal transplantation treated with sirolimus:: Clinical, microbiologic, histologic, therapeutic, and pathogenic aspects
Emmanuel Mahe et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Influence of pancreas transplantation alone on native renal function
T. Genzini et al.
TRANSPLANTATION PROCEEDINGS (2006)
Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials
Angela C. Webster et al.
TRANSPLANTATION (2006)
Brief communication:: Sirolimus-associated pneumonitis:: 24 cases in renal transplant recipients
L Champion et al.
ANNALS OF INTERNAL MEDICINE (2006)
Resolution of sirolimus-induced pneumonitis after conversion to everolimus
B. Rehm et al.
TRANSPLANTATION PROCEEDINGS (2006)
Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation
T Naito et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2006)
Mycophenolate mofetil and sirolimus combination in renal transplantation
J. M. Grinyo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment
DG Maluf et al.
TRANSPLANTATION (2005)
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin:: The ALERT extension study
H Holdaas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation
D Cattaneo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state
O Thaunat et al.
TRANSPLANTATION (2005)
Proteinuria following a switch from calcineurin inhibitors to sirolimus
E Letavernier et al.
TRANSPLANTATION (2005)
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation
CJE Watson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients
S Vítko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus
A Teutonico et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Everolimus versus mycophenolate mofetil in the prevention of rejection in de Novo renal transplant recipients: A 3-year randomized, multicenter, phase III study
MI Lorber et al.
TRANSPLANTATION (2005)
Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis
D Scheuner et al.
NATURE MEDICINE (2005)
Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients
FLL Wu et al.
PHARMACOTHERAPY (2005)
Rabbit antithyrnocyte globulin: A postoperative risk factor for sirolimus-treated renal transplant patients?
C Benavides et al.
TRANSPLANTATION PROCEEDINGS (2005)
Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy
CC Rogers et al.
TRANSPLANTATION PROCEEDINGS (2005)
Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy
E Mahé et al.
TRANSPLANTATION (2005)
Gastrointestinal leukocytoclastic vasculitis: An adverse effect of sirolimus
S Nagarajan et al.
PEDIATRIC TRANSPLANTATION (2005)
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies
S Vitko et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation
A Azzola et al.
TRANSPLANTATION (2004)
Randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year
G Cianci et al.
TRANSPLANTATION (2004)
Therapeutic drug monitoring of sirolimus: Effect of concomitant immunosuppressive therapy and optimization of drug dosing
D Cattaneo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study
B Nashan et al.
TRANSPLANTATION (2004)
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction
F Diekmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus
PG Dean et al.
TRANSPLANTATION (2004)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients
DRJ Kuypers et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience
E Morelon et al.
TRANSPLANTATION PROCEEDINGS (2003)
Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil.
T van Gelder et al.
TRANSPLANTATION (2003)
Thrombotic micro-angiopathy with sirolimus-based immunosuppression:: Potentiation of calcineurin-inhibitor-induced endothelial damage?
M Robson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Sirolimus may promote thrombotic microangiopathy
JA Saikali et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients
RM Langer et al.
TRANSPLANTATION (2002)
Sirolimus-induced leukocytoclastic vasculitis
KL Hardinger et al.
TRANSPLANTATION (2002)
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
D Cattaneo et al.
KIDNEY INTERNATIONAL (2002)
Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients
RC Hoogeveen et al.
TRANSPLANTATION (2001)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes
BD Kahan et al.
TRANSPLANTATION PROCEEDINGS (2001)
Clinical pharmacokinetics of sirolimus
K Mahalati et al.
CLINICAL PHARMACOKINETICS (2001)
Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients
E Morelon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
BD Kahan
LANCET (2000)
Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A
ZA Massy et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2000)
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
JC Hong et al.
TRANSPLANTATION (2000)
Share Paper
